

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,915-Conf. #5262
				Filing Date	March 12, 2007
				First Named Inventor	David Wallach
				Art Unit	1647
				Examiner Name	E. G. Stoica
Sheet	1	of	5	Attorney Docket Number	30694/41943

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-4,036,945	07-19-1977	Haber	
	A2	US-4,107,937	08-22-1978	Chmiel et al.	
	A3	US-4,117,881	10-03-1978	Williams et al.	
	A4	US-4,331,647	05-25-1982	Goldenberg	
	A5	US-4,481,946	11-13-1984	Altshuler et al.	
	A6	US-4,486,188	12-04-1984	Altshuler et al.	
	A7	US-4,816,567	03-28-1989	Cabilly et al.	
	A8	US-4,946,778	08-07-1990	Ladner et al.	
	A9	US-5,451,210	09-19-1995	Kramer et al.	
	A10	US-5,464,764	11-07-1995	Capecchi et al.	
	A11	US-5,487,992	01-30-1996	Capecchi et al.	
	A12	US-5,545,806	08-13-1996	Lonberg et al.	
	A13	US-5,545,807	08-13-1996	Surani et al.	
	A14	US-5,569,825	10-29-1996	Lonberg et al.	
	A15	US-5,625,126	04-29-1997	Lonberg et al.	
	A16	US-5,633,425	05-27-1997	Lonberg et al.	
	A17	US-5,661,016	08-26-1997	Lonberg et al.	
	A18	US-6,043,094	03-28-2000	Martin et al.	
	A19	US-6,224,904	05-01-2001	Rapp et al.	
	A20	US-6,326,174	12-04-2001	Joyce et al.	
	A21	US-6,342,611	01-29-2002	Weber et al.	
	A22	US-6,599,505	07-29-2003	Rosenblum	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO-1991/09955	07-11-1991	Applied Research Systems et al.		
	B2	WO-1999/25832	05-27-1999	The Board of Trustees of Leland Stanford Junior University		
	B3	WO-2001/10383	02-15-2001	Vertex Pharmaceuticals Inc.		
	B4	WO-2001/94351	12-13-2001	Vertex Pharmaceuticals Inc.		
	B5	WO-2003/20767	03-13-2003	Yeda Research and Development Co. Ltd.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,915-Conf. #5262
				Filing Date	March 12, 2007
				First Named Inventor	David Wallach
				Art Unit	1647
				Examiner Name	E. G. Stoica
Sheet	2	of	5	Attorney Docket Number	30694/41943

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C1	ALAM et al., Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells, J. Exp. Med., 190:1879-1890, 1999.		
	C2	AOKI et al., <i>In vivo</i> transfer efficiency of antisense oligonucleotides into the myocardium using HVJ-liposome method, Biochem. Biophys. Res. Commun., 231:540-545, 1997.		
	C3	BERNSTEIN, Role for a bidentate ribonuclease in the initiation step of RNA interference, Nature, 409:363-366, 2001.		
	C4	BIRD et al., Single-chain antigen-binding proteins, Science, 242:423-426, 1988.		
	C5	BLANCHARD et al., The three-dimensional structure of caspase-8: an initiator enzyme in apoptosis, Structure, 7:1125-1133, 1999.		
	C6	BOERNER et al., Production of antigen-specific human monoclonal antibodies from <i>in vitro</i> -primed human splenocytes, J. Immunol., 147:86-95, 1991.		
	C7	BOISSONNAS et al., Differential requirement of caspases during naive T cell proliferation, Eur. J. Immunol., 32:3007-3015, 2002.		
	C8	BOLDIN et al., Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death, Cell, 85:803-815, 1996.		
	C9	BRANTL, Antisense-RNA regulation and RNA interference, Biochem. Biophys. Acta, 1575:15-25, 2002.		
	C10	BREAKER et al., A DNA enzyme with Mg <sup>2+</sup> -dependent RNA phosphoesterase activity, Chem. Biol., 2:655-660, 1995.		
	C11	BROXMEYER, Colony assays of hematopoietic progenitor cells and correlations to clinical situations, Crit. Rev. Oncol. Hematol., 1:227-257, 1983.		
	C12	CHAUDHARY et al., Activation of the c-Jun N-terminal kinase/stress-activated protein kinase pathway by overexpression of caspase-8 and its homologs, J. Biol. Chem., 274:19211-19219, 1999.		
	C13	CHLICHLIA et al., Caspase activation is required for nitric oxide-mediated CD95 (Apo1/Fas)-dependent and independent apoptosis in human neoplastic lymphoid cells, Blood, 91:4311-4320, 1998.		
	C14	CHOU et al., Prediction of the tertiary structure and substrate binding site of caspase-8, FEBS Lett., 419:49-54, 1997.		
	C15	CHUN et al., Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency, Nature, 419:395-399, 2002.		
	C16	CLAUSEN et al., Conditional gene targeting in macrophages and granulocytes using LysMcre mice, Transgenic Res., 8:265-277, 1999.		
	C17	COLETTI et al., TNF $\alpha$ inhibits skeletal myogenesis through a PW1-dependent pathway by recruitment of caspase pathways, EMBO J., 21:631-642, 2002.		
	C18	CULLEN, RNA interference: antiviral defense and genetic tool, Nat. Immunol., 3:597-599, 2002.		
	C19	DE MARIA et al., Negative regulation of erythropoiesis by caspase-mediated cleavage of GATA-1, Nature, 401:489-493, 1999..		
	C20	FAOUZI et al., Anti-Fas induces hepatic chemokines and promotes inflammation by an NF-kappa B-independent, caspase-3-dependent pathway, J. Biol. Chem., 276:49077-49082, 2001.		
	C21	FISHWILD et al., High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice, Nat. Biotechnol., 14:845-851, 1996.		
	C22	GAGNETEN et al., Brief expression of a GFP cre fusion gene in embryonic stem cells allows rapid retrieval of site-specific genomic deletions, Nuc. Acids Res., 25:3326-3331, 1997.		

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,915-Conf. #5262
				Filing Date	March 12, 2007
				First Named Inventor	David Wallach
				Art Unit	1647
				Examiner Name	E. G. Stoica
Sheet	3	of	5	Attorney Docket Number	30694/41943

C23	GERWITZ, Oligonucleotide therapeutics: clothing the emperor, Curr. Opin. Mol. Ther., 1:297-306, 1999.
C24	GUSTAFSSON et al., Tie-1-directed expression of Cre recombinase in endothelial cells of embryoid bodies and transgenic mice, J. Cell Sci., 114:671-676, 2001.
C25	HOLMLUND et al., Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development, Curr. Opin. Mol. Ther., 1:372-385, 1999.
C26	INBAR et al., Localization of antibody-combining sites within the variable portions of heavy and light chains, Proc. Natl. Acad. Sci. (USA), 69:2659-2662, 1972.
C27	ITOH et al., Inhibition of urokinase receptor (uPAR) expression by RNA-cleaving catalytic DNA (DNAzyme) containing antisense uPAR [abstract 409], Mol. Ther., 5:S134, 2002.
C28	JONES et al., Replacing the complementarity-determining regions in a human antibody with those from a mouse, Nature, 321:522-525, 1986.
C29	KABRA et al., T cell-specific FADD-deficient mice: FADD is required for early T cell development, Proc. Natl. Acad. Sci. (USA), 98:6307-6312, 2001.
C30	KENNEDY et al., Caspase activation is required for T cell proliferation, J. Exp. Med., 190:1891-1896, 1999.
C31	KHACHIGIAN, DNazymes: cutting a path to a new class of therapeutics, Curr. Opin. Mol. Ther., 4:119-121, 2002.
C32	KHOSHNNAN, Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity, Proc. Natl. Acad. Sci. (USA), 99:1002-1007, 2002.
C33	KIM et al., Apoptosis by pan-caspase inhibitors in lipopolysaccharide-activated macrophages, Am. J. Physiol. Lung Cell. Mol. Physiol., 281:L1095-L1105, 2001.
C34	KRONENWETT et al., Oligodeoxyribonucleotide uptake in primary human hematopoietic cells is enhanced by cationic lipids and depends on the hematopoietic cell subset, Blood, 91:852-862, 1998.
C35	KÜHN et al., Inducible gene targeting in mice, Science, 269:1427-1429, 1995.
C36	LARRICK et al., PCR amplification of antibody genes, Methods, 2:106-110, 1991.
C37	LAVIGNE et al., Enhanced antisense inhibition of human immunodeficiency virus type 1 in cell cultures by DLS delivery system, Biochem. Biophys. Res. Commun., 237:566-571, 1997.
C38	LONBERG et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature, 368:856-859, 1994.
C39	LUFT, Making sense out of antisense oligodeoxynucleotide delivery: getting there is half the fun, J. Mol. Med., 76:75-76, 1998.
C40	MALIK et al., Retroviral-mediated gene expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters, Blood, 86:2993-3005, 1995.
C41	MARKS et al., By-passing immunization: human antibodies from V-gene libraries displayed on phage, J. Mol. Biol., 222:581-597, 1991.
C42	MATVEEVA et al., Prediction of antisense oligonucleotide efficacy by <i>in vitro</i> methods, Nat. Biotechnol., 16:1374-1375, 1998.
C43	MORRISON, Immunology: success in specification, Nature, 368:812-813, 1994.
C44	MUZIO et al., FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex, Cell, 85:817-827, 1996.
C45	NEUBERGER, Generating high-avidity human Mabs in mice, Nat. Biotechnol., 14:826, 1996.
C46	NEWTON et al., A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes, EMBO J., 17:706-718, 1998.
C47	OLSON et al., Caspase activity is required for stimulated B lymphocytes to enter the cell cycle, J. Immunol., 170:6065-6072, 2003.
C48	PORTER, The hydrolysis of rabbit $\gamma$ -globulin and antibodies with crystalline papain, Biochem. J., 73:119-126, 1959.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,915-Conf. #5262
				Filing Date	March 12, 2007
				First Named Inventor	David Wallach
				Art Unit	1647
				Examiner Name	E. G. Stoica
Sheet	4	of	5	Attorney Docket Number	30694/41943

C49	PRESTA, Antibody engineering, Curr. Opin. Struct. Biol., 2:593-596, 1992.	
C50	RAJUR et al., Covalent protein-oligonucleotide conjugates for efficient delivery of antisense molecules, Bioconj. Chem., 8:935-940, 1997.	
C51	RICKERT et al., B lymphocyte-specific, Cre-mediated mutagenesis in mice, Nuc. Acids Res., 25:1317-1318, 1997.	
C52	SAKAMAKI et al., <i>Ex vivo</i> whole-embryo culture of caspase-8-deficient embryos normalize their aberrant phenotypes in the developing neural tube and heart, Cell Death Differ., 9:1196-1206, 2002.	
C53	SALMENA et al., Essential role for caspase 8 in T-cell homeostasis and T-cell-mediated immunity, Genes Dev., 17:883-895, 2003.	
C54	SANTORO et al., A general purpose RNA-cleaving DNA enzyme, Proc. Natl. Acad. Sci. (USA), 94:4262-4266, 1997.	
C55	SCAFFIDI et al., Two CD95 (APO-1/Fas) signaling pathways, EMBO J., 17:1675-1687, 1998.	
C56	SCHUCHMANN et al., Dominant negative MORT1/FADD rescues mice from CD95 and TNF-induced liver failure, Hepatology, 37:129-135, 2003.	
C57	SEGURA et al., Inhibition of programmed cell death impairs <i>in vitro</i> vascular-like structure formation and reduces <i>in vivo</i> angiogenesis, FASEB J., 16:833-841, 2002.	
C58	SHARP, RNA interference—2001, Genes Dev., 15:485-490, 2001.	
C59	SHI, Mol. Cell. Biol., Mechanisms of caspase activation and inhibition during apoptosis, 9:459-470, 2002.	
C60	SORDET et al., Specific involvement of caspases in the differentiation of monocytes into macrophages, Blood, 100:4446-4453, 2002.	
C61	SROUR et al., Regulation of human factor IX expression using doxycycline-inducible gene expression system, Thromb. Haemost., 90:398-405, 2003.	
C62	STEGH et al., Inactivation of caspase-8 on mitochondria of Bcl-xL-expressing MCF7-Fas cells: role for the bifunctional apoptosis regulator protein, J. Biol. Chem., 277:4351-4360, 2002.	
C63	STEIN et al., Bone tissue specific transcriptional control: options for targeting gene therapy to the skeleton, Cancer, 88:2899-2902, 2000.	
C64	TUSCHL, RNA interference and small interfering RNAs, Chem. Biochem., 2:239-245, 2001.	
C65	UNO et al., Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells, Cancer Res., 61:7855-7860, 2001.	
C66	VARFOLOMEEV et al., Targeted disruption of the mouse caspase 8 gene ablates cell death induction by the TNF receptors Fas/Apol, and DR3 is lethal prenatally, Immunity, 9:267-276, 1998.	
C67	VERHOEYEN et al., Reshaping human antibodies: grafting an antilysozyme activity, Science, 239:1534-1536, 1988.	
C68	WALSH et al., A role for FADD in T cell activation and development, Immunity, 8:439-449, 1998.	
C69	WALTON et al., Prediction of antisense oligonucleotide binding affinity to a structured RNA target, Biotechnol. Bioeng., 65:1-9, 1999.	
C70	WANG et al., Roles of caspases in apoptosis, development, and cytokine maturation revealed by homozygous gene deficiencies, J. Cell Sci., 113:753-757, 2000.	
C71	WATT et al., The atomic-resolution structure of human caspase-8, a key activator of apoptosis, Structure, 7:1135-1143, 1999.	
C72	WELCH et al., Expression of ribozymes in gene transfer systems to modulate target RNA levels, Curr. Opin. Biotechnol., 9:486-496, 1998.	
C73	WELCH et al., Ribozyme gene therapy for hepatitis C virus infection, Clin. Diagn. Virol., 10:163-171, 1998.	
C74	YIN et al., Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis, Nature, 400:886-891, 1999.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/575,915-Conf. #5262
				Filing Date	March 12, 2007
				First Named Inventor	David Wallach
				Art Unit	1647
				Examiner Name	E. G. Stoica
Sheet	5	of	5	Attorney Docket Number	30694/41943

	C75	ZENDER et al., Caspase 8 small interfering RNA prevents acute liver failure in mice, Proc. Natl. Acad. Sci. (USA), 100:7797-7802, 2003.	
	C76	ZHANG et al., Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1, Nature, 392:296-300, 1998.	
	C77	ZÖRNIG et al., p53-dependent impairment of T-cell proliferation in FADD dominant-negative transgenic mice, Curr. Biol., 8:467-470, 1998.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.